Shringarpure R

ORCID: 0000-0001-5936-0447 · 1 paper in corpus
2013
A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.
Therapeutic advances in gastroenterology ·doi:10.1177/1756283x13491798

ObjectivesAdverse events (AEs) of ischemic colitis (IC) and complications of constipation (CoC) associated with alosetron are rare and have been adjudicated during the first 5.5 years of the risk management program (RMP); however, changes i…